Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

APOBEC3G exerts tumor suppressive effects in human hepatocellular carcinoma.

Chang LC, Kuo TY, Liu CW, Chen YS, Lin HH, Wu PF.

Anticancer Drugs. 2014 Apr;25(4):456-61. doi: 10.1097/CAD.0000000000000082.

PMID:
24500029
2.

APOBEC3B: a potential factor suppressing growth of human hepatocellular carcinoma cells.

Wu PF, Chen YS, Kuo TY, Lin HH, Liu CW, Chang LC.

Anticancer Res. 2015 Mar;35(3):1521-7.

PMID:
25750306
3.

Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo.

Lei YC, Hao YH, Zhang ZM, Tian YJ, Wang BJ, Yang Y, Zhao XP, Lu MJ, Gong FL, Yang DL.

World J Gastroenterol. 2006 Jul 28;12(28):4492-7.

4.

RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.

Xue WJ, Li C, Zhou XJ, Guan HG, Qin L, Li P, Wang ZW, Qian HX.

J Gastroenterol Hepatol. 2008 Sep;23(9):1448-58. Epub 2007 Aug 6.

PMID:
17683489
5.

Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.

Cao Y, Chen J, Wang D, Peng H, Tan X, Xiong D, Huang A, Tang H.

Oncotarget. 2015 Nov 10;6(35):38093-106. doi: 10.18632/oncotarget.5642.

6.
7.

HBsAg inhibits the translocation of JTB into mitochondria in HepG2 cells and potentially plays a role in HCC progression.

Liu YP, Yang XN, Jazag A, Pan JS, Hu TH, Liu JJ, Guleng B, Ren JL.

PLoS One. 2012;7(5):e36914. doi: 10.1371/journal.pone.0036914. Epub 2012 May 15.

8.

Modulation of hepatitis B surface antigen secretion by annexin II expressed in hepatitis B virus‑producing hepatoma cells.

Liu Y, Gao P.

Mol Med Rep. 2014 Dec;10(6):3113-7. doi: 10.3892/mmr.2014.2602. Epub 2014 Sep 30.

PMID:
25270731
9.

N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.

Lei YC, Tian YJ, Ding HH, Wang BJ, Yang Y, Hao YH, Zhao XP, Lu MJ, Gong FL, Yang DL.

World J Gastroenterol. 2006 Dec 14;12(46):7488-96.

10.

Inhibition of hepatitis B virus gene expression and replication by artificial microRNA.

Gao YF, Yu L, Wei W, Li JB, Luo QL, Shen JL.

World J Gastroenterol. 2008 Aug 7;14(29):4684-9.

11.

T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity.

Thielen BK, Klein KC, Walker LW, Rieck M, Buckner JH, Tomblingson GW, Lingappa JR.

PLoS Pathog. 2007 Sep 21;3(9):1320-34.

12.

The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses.

Fehrholz M, Kendl S, Prifert C, Weissbrich B, Lemon K, Rennick L, Duprex PW, Rima BK, Koning FA, Holmes RK, Malim MH, Schneider-Schaulies J.

J Gen Virol. 2012 Mar;93(Pt 3):565-76. doi: 10.1099/vir.0.038919-0. Epub 2011 Dec 14.

PMID:
22170635
13.

Overexpression of p42.3 promotes cell growth and tumorigenicity in hepatocellular carcinoma.

Sun W, Dong WW, Mao LL, Li WM, Cui JT, Xing R, Lu YY.

World J Gastroenterol. 2013 May 21;19(19):2913-20. doi: 10.3748/wjg.v19.i19.2913.

14.

APOBEC3G directly binds Hepatitis B virus core protein in cell and cell free systems.

Zhao D, Wang X, Lou G, Peng G, Li J, Zhu H, Chen F, Li S, Liu D, Chen Z, Yang Z.

Virus Res. 2010 Aug;151(2):213-9. doi: 10.1016/j.virusres.2010.05.009. Epub 2010 May 25.

PMID:
20510315
15.

[Immune response of HBsAg gene-modified dendritic cell-based vaccine in HepG2. 2. 15 hepatocellular carcinoma cells].

Yang JY, Liu WC, Cao DY, Si XM, Teng ZH.

Zhonghua Zhong Liu Za Zhi. 2007 Oct;29(10):728-32. Chinese.

PMID:
18396682
16.

[Inhibition of hepatitis B and duck hepatitis B virus replication by APOBEC3G].

Lei YC, Ma T, Hao YH, Zhang ZM, Tian YJ, Wang BJ, Yang DL.

Zhonghua Gan Zang Bing Za Zhi. 2006 Oct;14(10):738-41. Chinese.

PMID:
17064466
17.

HBsAg blocks TYPE I IFN induced up-regulation of A3G through inhibition of STAT3.

Xu F, Song H, Li N, Tan G.

Biochem Biophys Res Commun. 2016 Apr 22;473(1):219-23. doi: 10.1016/j.bbrc.2016.03.082. Epub 2016 Mar 19.

PMID:
27003258
18.

An occult hepatitis B-derived hepatoma cell line carrying persistent nuclear viral DNA and permissive for exogenous hepatitis B virus infection.

Lin CL, Chien RN, Lin SM, Ke PY, Lin CC, Yeh CT.

PLoS One. 2013 May 29;8(5):e65456. doi: 10.1371/journal.pone.0065456. Print 2013.

19.

Defective DNA damage response and repair in liver cells expressing hepatitis B virus surface antigen.

Chung YL.

FASEB J. 2013 Jun;27(6):2316-27. doi: 10.1096/fj.12-226639. Epub 2013 Feb 26.

20.

Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.

Yang JY, Cao DY, Xue Y, Yu ZC, Liu WC.

Hum Immunol. 2010 Mar;71(3):255-62. doi: 10.1016/j.humimm.2009.12.010. Epub 2010 Jan 8.

PMID:
20036295

Supplemental Content

Support Center